Pharma News
31 Aug 2025 to 06 Sep 2025
Sep 6, 2025
WHO includes weight-loss medications in its essential medicines list for adults worldwide.
The WHO has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity treatment. The agency urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are high. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 6, 2025
WHO supports weight-loss medications and calls for affordable generic options - Medical Xpress
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 6, 2025
Exploring AstraZeneca's Commitment to Sustainable Growth and Research & Development for Long-Term Value Generation.
AstraZeneca (LON:AZN) has achieved a 61% total return over five years, driven by strong financials and a robust R&D pipeline. With $28 billion in revenue for H1 2025, oncology sales lead growth. The company’s 189-drug pipeline includes innovative therapies like AZD0022 and AZD0120. AstraZeneca aims for $80 billion in annual revenue by 2030, positioning itself for long-term investor success.
Sep 6, 2025
WHO Designates Diabetes Medications as Essential, Indian Companies Gear Up for GLP-1 Generic Production Amid ...
The WHO has added GLP-1 drugs, including Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly), to its Essential Medicines List, enhancing access for type 2 diabetes patients. This decision encourages Indian firms like Dr. Reddy's Laboratories and Cipla to produce generics, aiming to reduce treatment costs and improve healthcare equity for over 800 million diabetes sufferers globally.
Sep 6, 2025
In July, there was a 5 percent increase in the import of bulk pharmaceuticals and their intermediates, according to DrugsControl Media Services.
Imports of bulk drugs and intermediates to India increased by 5% in July 2025, despite a cumulative decline of 3.8% over the first four months of the fiscal year.
Sep 6, 2025
US FDA increases regulations on imports of obesity drug components due to safety issues.
The U.S. Food and Drug Administration has tightened controls on imports of GLP-1 drug ingredients, commonly used in obesity treatments, due to rising safety concerns. This move aims to ensure the safety and efficacy of weight loss and diabetes medications.
Sep 6, 2025
DPIIT enters into an agreement with Pfizer and DrugsControl Media Services.
The Department for Promotion of Industry and Internal Trade (DPIIT) signed a Memorandum of Understanding (MoU) with Pfizer Limited on September 4, 2025, aimed at enhancing India's healthcare innovation ecosystem. This collaboration is expected to foster advancements in the pharmaceutical sector.
Sep 6, 2025
WHO Includes GLP-1 Medications in Essential Medicines List | Newsmax.com
The World Health Organization has added GLP-1 drugs, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list to enhance global access for diabetes treatment. The list aims to improve availability of costly medications, with a focus on patients with cardiovascular disease, chronic kidney disease, or obesity. The WHO also included Vertex Pharmaceuticals' Trikafta and Merck's Keytruda for cystic fibrosis and cancer, respectively.
Sep 6, 2025
Mounjaro and Ozempic receive approval from WHO, included in essential medications for diabetes and obesity treatment.
The World Health Organisation has added GLP-1 drugs, including Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, to its essential medicines list to enhance access for diabetes patients. This decision aims to lower costs and encourage generic production as patents expire. The list also includes Vertex Pharmaceuticals’ Trikafta and Merck’s Keytruda, emphasizing the WHO's commitment to essential treatments globally.
Sep 6, 2025
Sanofi's Amlitelimab Setback: Is This a Chance to Invest or a Red Flag? - AInvest
Sanofi's Phase III trial results for amlitelimab, an OX40-ligand monoclonal antibody for atopic dermatitis, showed significant skin clearance but fell short of expectations compared to Dupixent. Following the announcement, Sanofi's shares dropped over 10%, erasing nearly $13 billion in market value. Despite this setback, Sanofi's diverse pipeline and strategic acquisitions signal potential for future growth in immunology.
Sep 6, 2025
Ionis Pharmaceuticals Announces Olezarsen's Effectiveness in Lowering Triglycerides and Preventing Acute Pancreatitis in ...
Ionis Pharmaceuticals announced positive results from a late-stage trial of its investigational drug olezarsen, marketed as Tryngolza. The study showed significant reductions in triglyceride levels and a decrease in acute pancreatitis events among patients. Analysts suggest these findings could lead to a strong commercial launch for olezarsen as a first-in-class treatment for elevated triglycerides.
Sep 6, 2025
Research Connects Use of Injectable Contraceptive DMPA After Age 31 to Higher Risk of Meningioma
A recent study has linked the use of depot medroxyprogesterone acetate (DMPA), an injectable contraceptive, to an increased risk of meningioma in women, particularly those who start using it after age 31 or use it for extended periods. The findings raise concerns about the long-term health implications of hormonal contraceptives.
Sep 6, 2025
17760 prohibited capsules seized during inspection; suspect apprehended - Drug Enforcement
A joint team of drug inspectors and police seized 17,760 banned capsules during a routine check at Badigarh intersection in Bijnor on September 6, 2025. The operation led to the arrest of the accused involved in the illegal distribution of these drugs.
Sep 6, 2025
Ingredient in Ozempic included in WHO's essential medicines list
The World Health Organization has added GLP-1 drugs, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list to improve access for diabetes treatment. This decision aims to address high prices limiting availability, with hopes for increased generic production as patents expire. The list also includes Vertex's Trikafta for cystic fibrosis and Merck's Keytruda for cancer.
Sep 6, 2025
Patent granted for a silk nanogel injector designed for precise drug delivery | Bhubaneswar News
A team of scientists from Odisha and West Bengal has received a patent for the silk nano gel injector, a device designed for controlled and targeted drug delivery. Utilizing silk fibroin-based nanogels, the injector enhances treatment effectiveness while minimizing side effects. It shows promise in cancer therapy, wound healing, and regenerative medicine, marking a significant advancement in precision medicine.
Sep 6, 2025
Regulatory Dilemma: FDA Actions and the Transformation of the Worldwide GLP-1 Supply Chain
The global GLP-1 receptor agonist market, valued at $13.84 billion in 2024, is expected to reach $48.84 billion by 2030, driven by drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Regulatory actions by the FDA and increased M&A activity, particularly involving Novo Nordisk and Eli Lilly, are shaping the sector's landscape amid rising costs and access challenges.
Sep 6, 2025
Today's Analysis of Merck & Co., Inc. (MRK) Stock: An In-Depth Look at Market Trends and Business Operations
Merck & Co., Inc. (MRK) saw its stock rise to $84.37 on September 5, 2025, reflecting positive market sentiment. The company, known for its oncology drug Keytruda and vaccines like Gardasil, maintains strong revenue growth and a robust R&D pipeline. However, it faces risks from patent expirations and competition. Merck is well-positioned for future growth in the pharmaceutical market.
Sep 6, 2025
Regulatory body determines that the obesity advertisements from Ozempic's manufacturer were permissible (as they did not ... - The Journal
The Health Products Regulatory Authority (HPRA) has deemed Novo Nordisk's advertising campaign for obesity awareness compliant with Irish law, as it did not reference specific medicines like Ozempic and Wegovy. The campaign, featuring the tagline “It’s about my health, not just my weight,” aimed to educate the public on obesity without directly promoting its products.
Sep 6, 2025
WHO supports the use of weight-loss medications for managing diabetes and obesity - Global - DAWN.COM
The World Health Organisation has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to improve access in developing countries, where high costs hinder availability. Research suggests generic semaglutide could be produced for as low as $4 a month.
Sep 5, 2025
Stephen Saad anticipates $50 million in revenue from Aspen's weight-loss medication - Billionaires.Africa
Stephen Saad, CEO of Aspen Pharmacare Holdings, anticipates that the company's new injector pen version of Mounjaro could exceed $50 million in sales within two years following its regulatory approval in South Africa. This move positions Aspen against Novo Nordisk in the growing GLP-1 market, driven by rising diabetes and obesity rates. Aspen is also pursuing broader approvals across sub-Saharan Africa.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options - Jamaica Observer
The World Health Organisation (WHO) has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, highlighting the need for lower prices to combat obesity-related deaths, which exceeded 3.7 million in 2021.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options | GMA News Online
The World Health Organization (WHO) has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options.
The World Health Organisation has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are high. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options.
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options.
Ozempic, a leading drug in the new class of weight-loss medications known as GLP-1s, has gained significant attention for its effectiveness in promoting weight loss.
Sep 5, 2025
Pair Arrested for Selling Counterfeit Branded Medications, Reports DrugsControl Media Services
Uttarakhand Special Task Force has arrested a couple, Pradeep Kumar and his wife, in Zirakpur, Punjab, for distributing counterfeit branded medicines. This operation marks a significant success in combating the sale of fake pharmaceuticals.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options.
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are high. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options.
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for treating diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide is set to expire in several countries next year, potentially lowering costs.
Sep 5, 2025
What’s Causing the Decline in Sanofi's Stock on Thursday? - Benzinga
Sanofi SA's stock fell 8.59% after late-stage trial results for amlitelimab, a potential successor to Dupixent, did not meet investor expectations. While amlitelimab showed significant skin clearance in atopic dermatitis patients, it underperformed compared to Amgen's rocatinlimab and Dupixent. Analysts suggest OX40 therapies may be limited to second-line treatments due to slower responses.
Sep 5, 2025
WHO includes GLP-1 medications for diabetes and other conditions in its essential medicines list - Devdiscourse
The World Health Organization has added GLP-1 drugs, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list to enhance global access for diabetes treatment. This move aims to address high prices and encourage generic production. The list also includes Vertex Pharmaceuticals' Trikafta for cystic fibrosis and Merck's Keytruda for various cancers.
Sep 5, 2025
Treeline Biosciences Moves Three Cancer Treatments into Phase 1 Trials and Raises $200 Million...
Treeline Biosciences has advanced three cancer drug candidates into Phase 1 clinical trials and secured $200 million in funding to support its research and development. This marks a significant milestone for the company, co-founded by Josh Bilenker and Jeff Engelman, as it progresses its first clinical candidates since inception.
Sep 5, 2025
Aspen in South Africa aims to introduce more affordable weight-loss medications | Semafor
Aspen Pharmacare, Africa's largest drugmaker, plans to launch cheaper versions of weight-loss drugs Ozempic and Wegovy next year, aiming to capture a share of the $100 billion global market. The CEO stated these versions will be priced below half the average global cost, as patents expire in 2026. Aspen seeks to recover from a recent net loss of 1.1 billion rand.
Sep 5, 2025
Federal Judge Makes Ruling on Patent Compensation Matter in Mallinckrodt vs. Airgas Case | JD Supra
A Delaware federal judge has set the hypothetical negotiation date in the patent dispute between Mallinckrodt and Airgas over Mallinckrodt's INOmax and DSir Plus products to November 2023, coinciding with Airgas's launch of its Ulspira product. This decision impacts the calculation of damages and highlights the complexities of patent litigation in the pharmaceutical industry.
Sep 5, 2025
WHO includes Ozempic component in its essential medicines list | CBC News
The World Health Organization has added GLP-1 drugs, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list to enhance global access for diabetes treatment. The list also includes Vertex's Trikafta for cystic fibrosis and Merck's Keytruda for various cancers. The WHO aims to encourage generic production as patents expire, improving affordability for millions.
Sep 5, 2025
WHO Updates Essential Medicines List to Include Important Diabetes and Cancer Treatments | Health
The World Health Organization has updated its essential medicines list to include GLP-1 drugs from Novo Nordisk and Eli Lilly for diabetes, along with treatments for cystic fibrosis and cancer. This move aims to improve access to these expensive medications in underfunded health systems, promoting health equity and encouraging generic production post-patent expiration.
Sep 5, 2025
WHO includes Ozempic component in its essential medicines list | Radio-Canada.ca
The World Health Organization has added GLP-1 drugs, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list to enhance global access for diabetes treatment. The list aims to improve availability of costly medications, with a focus on generics as patents expire. Other additions include Vertex's Trikafta for cystic fibrosis and Merck's Keytruda for cancer.
Sep 5, 2025
WHO Urges Availability of Low-Cost Generic GLP-1 Medications for Obesity and Diabetes in Low-Income Nations
The WHO has added glucagon-like peptide-1 (GLP-1) drugs, including Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, to its essential medicines list to improve access for obesity and diabetes treatment in developing countries. The agency urges the production of affordable generics, highlighting the need for equitable healthcare as over 800 million people live with diabetes and more than one billion with obesity.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options.
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for treating diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options.
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for treating obesity and diabetes. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 5, 2025
WHO supports weight-loss medications and calls for affordable generic options.
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for treating diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are high. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 5, 2025
Worries for emerging countries: WHO supports weight-loss medications and calls for affordable generics - RTL Today
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are high. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 4, 2025
Sanofi Faces Disappointment as Successor to Key Drug Fails to Meet Investor Expectations - Benzinga
Sanofi SA's stock dropped 8.52% after late-stage trial results for amlitelimab, a potential successor to Dupixent, fell short of investor expectations. While the drug met primary endpoints for atopic dermatitis, analysts noted it underperformed compared to Dupixent and rival biologics. Amlitelimab's safety profile remains strong, with further data expected through 2026.
Sep 4, 2025
Can AbbVie's Neuroscience Division Sustain Its Revenue Growth? - TradingView
AbbVie (ABBV) has strengthened its neuroscience franchise, contributing over 17% to its sales in H1 2025, driven by drugs like Botox Therapeutic and Vraylar. The company recently launched Vyalev for Parkinson’s and acquired Gilgamesh Pharmaceuticals for $1.2 billion to enhance its pipeline. AbbVie’s shares have outperformed the industry, trading at a premium valuation.
Sep 4, 2025
Akeso's stock declines even as cancer drug sales soar - Bamboo Works
Akeso Inc. reported a 38% revenue increase to 1.41 billion yuan in the first half of 2024, driven by strong sales of its oncology drugs, including ivonescimab and cadonilimab. However, the company faced a widening net loss of 588 million yuan and share sales by founders, leading to a decline in investor confidence.
Sep 4, 2025
Pomerantz LLP Looks Into Possible Claims Related to Anika Therapeutics Shareholders
Pomerantz LLP has launched an investigation into potential claims for investors of Anika Therapeutics, Inc. (NASDAQ: ANIK). The firm is examining issues that may have affected shareholders and encourages impacted investors to contact them for more information. Further details regarding the claims or investigation scope have not been disclosed.
Sep 4, 2025
Batabyal: Insights on Drug Pricing for the US from International Policies | Long Island Business News
A recent analysis highlights the complexities of U.S. drug pricing, emphasizing the impact of patents, insurance, and physician behavior. Proposed solutions include advance market commitments, subscription pricing, and pay-for-performance contracts. The study suggests that while high drug prices are a concern, they are not the primary driver of overall healthcare costs, urging tailored policies to balance access and innovation.
Sep 4, 2025
FDA introduces a new evaluation process for medications aimed at ultra-rare conditions - BioPharma Dive
The FDA has introduced the Rare Disease Evidence Principles (RDEP) to streamline the approval process for drugs targeting ultra-rare conditions, allowing evidence from single-arm trials and other sources. This initiative aims to expedite the development of treatments for diseases affecting fewer than 1,000 people. Companies like Neurogene, Rocket Pharmaceuticals, Ultragenyx, and UniQure may benefit from this flexible approach.
Sep 4, 2025
The Patent for Ozempic Will Begin to Expire in 2026: What Lies Ahead? | CZ app
The global uptake of GLP-1 drugs, including semaglutide (Ozempic) and tirzepatide (Mounjaro), has been limited due to high costs and availability. However, with patents expiring in 2026, generics may reduce prices significantly, increasing access for millions. Companies like Novo Nordisk and Eli Lilly are experiencing soaring demand, while generic versions could reshape obesity treatment worldwide.
Sep 4, 2025
Oncotelic's CEO Dr. Trieu's Innovations Lead to $4.2 Billion in Biotech Acquisitions | OTLC Stock Update
Oncotelic Therapeutics, led by Dr. Vuong Trieu, is advancing its oncology and immunotherapy pipeline, including OT-101 for pancreatic cancer and AL-101 for Parkinson’s disease. Dr. Trieu, known for his extensive patent portfolio, has significantly impacted drug development, including the creation of Abraxane® and Cynviloq™. The company aims to deliver innovative therapies for high unmet medical needs.
Sep 4, 2025
Silo Pharma Obtains Australian Patent for Licensed Drug Candidate Targeting PTSD
Silo Pharma, Inc. announced that IP Australia has granted a patent for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress,” exclusively licensed to Silo by Columbia University. This patent strengthens the protection for Silo's lead asset, SPC-15, an intranasal treatment for PTSD, enhancing its clinical trial development plans.
Sep 4, 2025
Novartis Signs $5 Billion Licensing Agreement with Argo Therapeutics for RNA-Targeted ANGPTL3 Treatments
Novartis has signed a licensing deal with Argo Therapeutics valued at over $5 billion to develop RNA-based drugs targeting ANGPTL3, a protein linked to cardiovascular and metabolic diseases. This agreement grants Novartis exclusive global rights to Argo's therapies, including upfront and milestone payments, highlighting the growing interest in RNA therapeutics for complex diseases.
Sep 4, 2025
NMPA Unveils Proposed Guidelines for Data Protection (Data Exclusivity) - Lexology
In March 2025, China's NMPA proposed new draft measures for data protection, offering up to six years of exclusivity for innovative drugs, vaccines, and biologics, and three years for modified drugs and first generics. These measures aim to enhance domestic drug manufacturing and attract foreign drugs, reflecting China's ongoing efforts to strengthen its pharmaceutical data protection framework.
Sep 4, 2025
IRLAB Receives Patent Approval, Enhancing Market Exclusivity for Its Drug Candidate...
IRLAB Therapeutics has received an additional composition of matter patent in China for the salt form of mesdopetam, its leading drug candidate for Parkinson's disease. This patent extends market exclusivity potentially into the mid-2040s, enhancing the drug's value. Mesdopetam aims to treat levodopa-induced dyskinesias, affecting over 1.5 million individuals globally.
Sep 4, 2025
Zydus introduces VaxiFlu TM, the first trivalent influenza vaccine in India - Drug Control
Zydus Lifesciences Ltd. has launched its trivalent influenza vaccine, VaxiFlu, in India, marking its first introduction in the country. This launch aligns with the World Health Organization's global recommendations for flu vaccination.
Sep 4, 2025
GST reduced on essential medications and medical devices, according to DrugsControl Media Services.
In a significant move to enhance healthcare affordability, the GST Council has reduced tax rates on life-saving drugs and medical equipment. This decision aims to benefit millions of Indians, particularly those facing long-term and critical illnesses.
Sep 4, 2025
Drugs inspector apprehended for accepting a bribe in Arwal, according to DrugsControl Media Services.
Drugs Inspector Shailendra Narayan, stationed at Sadar Hospital in Arwal, was arrested by the Vigilance Investigation Bureau for accepting a bribe of Rs 40,000. The incident highlights ongoing corruption issues within the pharmaceutical regulatory framework.
Sep 4, 2025
Chinese Pharmaceutical Companies Advance HER2 ADCs in the Face of Enhertu's Market Leadership
Seven Chinese pharmaceutical companies are developing their own versions of Enhertu, a blockbuster cancer drug, to compete in the domestic market.
Sep 4, 2025
Sanofi Settles Zantac Cancer Lawsuits in Connecticut - USA Herald
Sanofi-Aventis US LLC and Sanofi US Services Inc. have reached settlements in two Connecticut lawsuits regarding the heartburn medication Zantac, which allegedly degrades into a cancer-causing compound. The settlements involve six and ten plaintiffs, respectively, and terms remain undisclosed. The lawsuits centered on innovator liability, holding brand-name manufacturers accountable for injuries from generic drugs.
Sep 4, 2025
Ionis Pharmaceuticals Reaches Record Levels as Analyst Predicts Major Success for Olezarsen. - AInvest
Ionis Pharmaceuticals (IONS) shares reached an all-time high after BMO Capital upgraded the stock to "outperform" and raised the price target to $70. This surge follows promising results from clinical trials for Olezarsen, which showed a 72% reduction in blood fat and an 85% decrease in acute pancreatitis events. The company plans to submit a supplemental new drug application to the FDA by year-end.
Sep 3, 2025
China's Efforts to Take Advantage of Shortages in Weight-Loss Medications | Business - Devdiscourse
Chinese pharmaceutical companies are capitalizing on U.S. supply shortages of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound by producing generics. Firms such as Hybio and Sinopep are eyeing markets like Canada and Brazil as key patents expire, despite regulatory challenges. The low production costs present a lucrative opportunity, though complexities in manufacturing may hinder rapid expansion.
Sep 3, 2025
Indian generic manufacturers intensify challenges to Novo Nordisk's patent for its weight-loss medication | MLex
Novo Nordisk faces intensified legal challenges in India as Hyderabad-based Natco Pharma files six new patent-infringement lawsuits against its weight-loss drug, semaglutide, marketed as Wegovy and Ozempic. This marks a significant escalation in the ongoing patent battle involving the Danish pharmaceutical giant.
Sep 3, 2025
Fake pharmaceutical production facility uncovered in Puducherry, with goods valued at ₹99.47 lakh confiscated.
A joint raid by the Central Drugs Standard Control Organisation (CDSCO) and Puducherry's Drugs Control Department uncovered an illegal drug manufacturing unit, seizing materials valued at ₹99.47 lakh, including empty capsules and tablets. The operation highlights ongoing efforts to combat spurious drug production in the region.
Sep 3, 2025
The exploitation of patent laws by major pharmaceutical companies | Practice - GxP News
President Trump's initiative to reduce prescription drug prices faces challenges due to systemic patent abuses by pharmaceutical companies. A RAND study highlights U.S. drug prices are nearly three times higher than in other nations. The FTC has begun challenging questionable patents on drugs like Bristol-Myers Squibb's Revlimid and AbbVie's Humira, aiming to curb monopolistic practices that inflate costs.
Sep 3, 2025
OBBBA alters the probabilities for the upcoming phase of US prescription drug price discussions - BioWorld
Oddsmakers are adjusting predictions for the third round of U.S. Inflation Reduction Act (IRA) price negotiations following the introduction of an orphan drug provision in the One Big Beautiful Bill Act (OBBBA), signed into law on July 4. This change could impact which drugs are targeted in the upcoming negotiations.
Sep 3, 2025
Aspen receives authorization for Mounjaro injection in South Africa, intensifying competition with Novo - KFGO
Aspen Pharmacare has received regulatory approval to launch the injector pen for Eli Lilly's diabetes drug Mounjaro in South Africa, enhancing competition with Novo Nordisk's Wegovy. Aspen aims to alleviate shortages and is also pursuing approval for Mounjaro's use in chronic weight management. The company plans to expand Mounjaro's availability across sub-Saharan Africa and Canada.
Sep 3, 2025
Merck's cholesterol medication receives a positive outcome from another late-stage clinical trial - Westlaw Today
Sep 3, 2025
Ionis Pharmaceuticals Receives Upgrade to Outperform from BMO Capital, Price Target Increased to $70 - AInvest
BMO Capital Markets has upgraded Ionis Pharmaceuticals (NASDAQ: IONS) to "Outperform" and raised its price target to $70, following positive late-stage trial results for olezarsen, a lipid-lowering agent. The trials showed significant benefits for acute pancreatitis in patients with severe hypertriglyceridemia. The FDA's upcoming approval of Ionis' HAE drug, Donidalorsen, may further enhance the company's market position.
Sep 3, 2025
Rousselot has received patents for its joint care component Colartix in Europe, Japan, and China.
Rousselot has secured patents for Colartix, a hydrolysed cartilage matrix designed to alleviate joint discomfort. The patented composition includes collagen hydrolysate and chondroitin sulfate, supported by scientific research. Colartix, launched in 2022, is gaining traction in the $4.4 billion joint health supplement market, with patents granted in Europe, Japan, and China, and pending in Brazil and the U.S.
Sep 3, 2025
Strategies for Maintaining Affordability of Cancer Medications Post-LDC Transition | The Daily Star
As Bangladesh approaches its 2026 graduation from Least Developed Country status, concerns rise over the potential loss of affordable cancer medications. The TRIPS waiver has allowed local companies like Beacon Pharmaceuticals to produce generics like Tagrix, but post-graduation, drug prices could soar by 20-50%. Urgent policy measures are needed to maintain access to lifesaving treatments.
Sep 3, 2025
Chinese Firms Expand into Generic Medications as US Weight-Loss Interest Declines - AInvest
Chinese companies are shifting towards producing generic weight-loss medications as sales for Eli Lilly and Company's products, including Zepbound, decline in the U.S. market. This trend is driven by the fading popularity of weight-loss drugs and the expiration of patents, allowing at least eight Chinese firms to supply raw materials for generics, despite challenges in manufacturing semaglutide.
Sep 3, 2025
Chinese firms shift focus to generic versions as patents on weight-loss medications lapse.
Chinese companies are racing to produce generic versions of Novo Nordisk's Wegovy, which has seen over a billion makeshift doses sold online in the U.S. However, the availability of cheap copies of Wegovy and Eli Lilly's Zepbound is declining due to regulatory restrictions. Former FDA chief Robert Califf noted the unprecedented demand for these weight-loss drugs.
Sep 2, 2025
STRATA Skin Sciences reinforces its patent collection for XTRAC laser treatments and broadens its CPT code offerings.
STRATA Skin Sciences has strengthened its patent portfolio for XTRAC excimer laser combination therapies with JAK inhibitors and biologic drugs. The company is collaborating with CMS to expand CPT codes for inflammatory skin conditions by 2026, potentially tripling its market. STRATA's strategic moves aim to enhance treatment options and secure a competitive edge in dermatological care.
Sep 2, 2025
NPPA sets retail prices for 42 newly approved medications, according to DrugsControl Media Services.
The National Pharmaceutical Pricing Authority (NPPA) has set the retail prices for 42 new drugs, including various anti-diabetes, anti-hypertension, antibiotics, and anti-inflammatory medications, in accordance with the Drugs Prices Control Order (DPCO), 2013.
Sep 2, 2025
Democrats Focus on Reducing High Prescription Costs - MarketReview
Democrats are increasingly focusing on high drug prices, particularly insulin, which can cost patients up to $3,000 monthly in the U.S. compared to just $21 in Canada. The article criticizes the U.S. pharmaceutical market's inefficiencies and calls for reforms, including allowing drug imports and addressing government protectionism that inflates prices, while highlighting the need for accountability in the FDA.
Sep 2, 2025
Axsome Therapeutics: Strengthening Market Leadership with Strategic Patent Strategies and ...
Axsome Therapeutics (AXSM) has successfully navigated the specialty pharma landscape by employing strategic patent litigation settlements and exclusivity agreements, particularly for its drugs Sunosi and Auvelity. These strategies delay generic competition until 2040, ensuring revenue stability and funding for innovation. Axsome's approach exemplifies resilience in a sector threatened by generics, making it a compelling investment opportunity.
Sep 2, 2025
China's Pharmaceutical Boom: The Competition to Create Generic Weight-Loss Medications | Business
Chinese companies are ramping up production of generic versions of Novo Nordisk's weight-loss drug Wegovy, aiming to capture the market amid U.S. shortages. Firms like Jiangsu Sinopep-Allsino Biopharmaceutical are focusing on international distribution despite regulatory challenges. While manufacturing semaglutide remains complex, suppliers are seizing profit opportunities, although shipment rates are declining.
Sep 2, 2025
STRATA Skin Sciences Secures Patent for Excimer-JAK Combination Therapy - Stock Titan
STRATA Skin Sciences, Inc. announced that its patent portfolio secures exclusivity for combination therapies using its XTRAC excimer laser with JAK inhibitors and biologic drugs, targeting conditions like vitiligo and psoriasis. The company aims to expand reimbursement eligibility for these treatments by 2026, enhancing market opportunities and patient care.
Sep 2, 2025
STRATA Skin Sciences Grows Its Patent Collection for Combination Treatments and Pursues CPT...
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced its patent portfolio supports the use of its XTRAC excimer laser in combination with JAK inhibitors and biologic drugs for treating dermatologic conditions. The company aims to expand reimbursement for these therapies by 2026, enhancing treatment options for conditions like psoriasis and vitiligo. STRATA's patents position it at the forefront of integrative dermatologic treatment.
Sep 2, 2025
Chinese firms are said to be shifting towards generics as shipments related to the U.S. weight-loss trend decline.
Chinese companies are advancing in producing generic versions of Novo Nordisk's Wegovy, supplying over a billion doses of weight-loss drugs online in the U.S. However, the availability of these cheap copies is declining due to regulatory restrictions. FDA's Robert Califf noted the unprecedented demand for Wegovy, leading to shortages and opportunities for compounding pharmacies.
Sep 2, 2025
Gilead Sciences to Raise Prices for HIV Medications Distributed via State AIDS Initiatives
Gilead Sciences plans significant price increases for its HIV treatments, including Descovy, provided through state AIDS Drug Assistance Programs (ADAPs). This move could impact access to these essential medications for low-income individuals, amid rising healthcare costs. Specific details on the price hikes have not been disclosed, but Gilead cites inflation and market factors as influences.
Sep 2, 2025
Are GLP-1 weight loss medications safe for children? Insights from a pediatrician - Cincinnati Enquirer
A recent study by the CDC reveals that prescriptions for weight loss medications, including Wegovy and Ozempic, have tripled among adolescents aged 12 to 17 from 2020 to 2023. Despite this increase, only 0.5% of obese teens were prescribed these drugs in 2023. Two new injectable medications have also been FDA-approved for this age group since 2020.
Sep 2, 2025
Uncommon Conditions Achieve Four FDA Milestones in August - BioSpace
In August, Jazz Pharmaceuticals' Modeyso for glioma, Insmed's Brinsupri for bronchiectasis, Precigen's Papzimeos for respiratory papillomatosis, and Ionis Pharmaceuticals' Dawnzera for hereditary angioedema received FDA approvals. Novo Nordisk's Wegovy was also approved for metabolic dysfunction-associated steatohepatitis, potentially adding $1.9 billion in sales. However, PTC Therapeutics faced a rejection for vatiquinone in Friedreich’s ataxia.
Sep 2, 2025
Clarivate is set to host the 16th annual Pharmavision India conference on September 3 at the Taj Krishna in Hyderabad.
Clarivate Plc. will host the 16th annual Pharmavision India conference on September 3, 2025, in Hyderabad. The event will gather global pharmaceutical leaders to discuss market shifts, patent expiries, and the rise of biosimilars. Key speakers include Henry Levy from Clarivate and Deepak Sapra from Dr Reddy’s Laboratories, focusing on strategies for sustainable growth and enhancing India's role in global healthcare.
Sep 2, 2025
DB raises Sanofi's rating to 'buy' due to the potential of its eczema medication - TradingView
Deutsche Bank has upgraded Sanofi (SAN) to "buy" from "hold," highlighting the promising potential of eczema drug amlitelimab ahead of its Phase 3 trial results. Amlitelimab is expected to generate half of Sanofi's pharmaceutical revenue by 2031, replacing Dupixent, which currently dominates the market. The price target has been raised by 22% to EUR 110.
Sep 2, 2025
Research Indicates Beta-Blockers May Be Ineffective and Potentially Harmful for Certain Individuals - KFF Health News
Recent studies reveal that beta-blockers, commonly used after heart attacks, offer no benefits for most patients and may increase the risk of death in some women, according to Dr. Borja Ibáñez. Meanwhile, Novo Nordisk's Wegovy has been shown to reduce heart attack and stroke risk by 57% compared to Eli Lilly's Mounjaro and Zepbound.
Sep 2, 2025
Novo's Wegovy Reduces Cardiovascular Risk by 57% Compared to Tirzepatide - BioSpace
Novo Nordisk's Wegovy has demonstrated a 57% reduction in major cardiovascular events compared to Eli Lilly's tirzepatide, according to the STEER study presented at the 2025 European Society of Cardiology Congress. Wegovy, approved for cardiovascular risk reduction in overweight patients, outperformed tirzepatide, which lacks such an indication. Novo's recent successes may help restore investor confidence amid a challenging year.
Sep 2, 2025
GSK Gains Approximately $5 Billion in Just One Month: Strategies for Investing in the Stock - The Globe and Mail
GSK's stock has surged 6.4% over the past month, adding nearly $5 billion to its market value, driven by strong performance in its Specialty Medicines unit, particularly in Oncology and HIV treatments like Nucala and Dovato. However, vaccine sales, including Shingrix and Arexvy, are declining in the U.S. GSK expects continued growth in Specialty Medicines, projecting over 7% sales growth through 2026.
Sep 2, 2025
Can Opdivo and Opdivo Qvantig Propel BMY's Revenue Growth? - TradingView
Bristol Myers Squibb (BMY) reports strong sales growth for its oncology drugs, particularly Opdivo and Opdivo Qvantig, following recent European approvals. Despite competition from Merck's Keytruda and Roche's Tecentriq, BMY anticipates mid to high single-digit sales growth for Opdivo in 2025. However, BMY shares have declined 13.6% year-to-date, trading at a discount compared to the industry.
Sep 2, 2025
Can Opdivo and Opdivo Qvantig Propel BMY's Revenue Growth? - The Globe and Mail
Bristol Myers Squibb (BMY) reports strong sales growth for its oncology drugs, particularly Opdivo and Opdivo Qvantig, following recent European approvals. Despite facing competition from Merck's Keytruda and Roche's Tecentriq, BMY anticipates mid to high single-digit sales growth for Opdivo and Qvantig in 2025. However, BMY shares have declined 13.6% year-to-date, trading at a discount compared to industry peers.
Sep 2, 2025
Latest trial outcomes enhance MSD's oral cholesterol medication - Irish Examiner
MSD announced that its oral drug successfully met the primary goal of reducing bad cholesterol in a late-stage trial, marking a second victory since June. This positive trial data bolsters the company's search for a new blockbuster candidate, as its key revenue driver, Keytruda, is set to lose patent protection by the decade's end.
Sep 2, 2025
Boryeong's top-selling hypertension medication "Kanav" will keep its current pricing for t..
Boryeong's hypertension drug "Kanav" will maintain its current pricing following a court decision that suspends planned price cuts due to the entry of generics. The Ministry of Health and Welfare confirmed that the existing prices for 11 Kanav-based products will remain until at least two months post-judgment, potentially delaying any price reductions until 2028.
Sep 2, 2025
Four company owners and plant managers apprehended for producing counterfeit branded medications.
Uttarakhand STF has arrested the owners and plant heads of four companies involved in manufacturing counterfeit medicines of branded firms. A total of ten individuals, including the gang's mastermind, have been apprehended in connection with this illegal operation.
Sep 1, 2025
Trends and Developments in the Long-Acting Drug Delivery Technologies and Services Market - Business Wire
The global long-acting drug delivery technologies and services market is projected to grow from USD 1.06 billion to USD 4.62 billion by 2035, at a CAGR of 13.1%. This growth is driven by advancements in drug delivery systems for various diseases, enhancing patient compliance and reducing healthcare costs, particularly in low/middle-income countries. Key players include Adare Pharma Solutions and Creative Biolabs.
Sep 1, 2025
Reevaluating Eli Lilly's Worth in Light of Market Changes - AInvest
Eli Lilly's stock (NYSE: LLY) has dropped 23% over the past year, leading analysts to deem it undervalued by 17.5%. Despite strong Q2 results, including $15.56 billion in revenue and $8.6 billion from its GLP-1 drugs Mounjaro and Zepbound, concerns over regulatory pressures and market reliance persist. Analysts suggest a hold strategy, with potential upside if bought below $750.
Sep 1, 2025
Lucrative opportunities in orphan medications - Down To Earth
The rise of orphan drugs, which treat rare diseases, has led to significant profits for pharmaceutical companies, with 52% of FDA-approved drugs last year targeting these conditions. However, access remains limited due to high costs and inadequate support in countries like India. The Union Ministry of Tribal Affairs recently announced the Birsa Munda Prize to incentivize research for sickle cell disease, marking a potential shift in addressing orphan diseases.
Sep 1, 2025
Sanofi obtains US authorization for oral ITP medication expected to be a major success - European Biotechnology Magazine
Sanofi's new ITP drug, rilzabrutinib, has received FDA approval based on the LUNA 3 Phase III study results. Analysts predict peak sales could reach $5 billion, as it is the only approved oral treatment that effectively targets Bruton’s tyrosine kinase. Rilzabrutinib is also under review in China and the EU, with potential applications in other autoimmune diseases.
Sep 1, 2025
Biogen Obtains FDA Approval for Subcutaneous Maintenance Dosing of Leqembi - TradingView
Biogen (BIIB) has received FDA approval for a subcutaneous autoinjector version of Leqembi, branded as Leqembi Iqlik, for weekly maintenance dosing in early Alzheimer's disease. This new option allows patients to transition from biweekly infusions to a quicker, at-home administration. Biogen plans to launch Leqembi Iqlik on October 6, 2025, following positive clinical study results.
Sep 1, 2025
Cutting-Edge Pharmaceutical Firm Raises $200 Million in Funding, Plans to Go Public in Hong Kong - 36氪
YingShi Biopharm, founded in 2017 by Wang Zaiqi, is set to list on the Hong Kong stock market, focusing on innovative anti-cancer drugs. Its core product, Ifebemtinib, a small-molecule FAK inhibitor, targets drug resistance in cancers like ovarian and lung cancer. The company has raised $130 million and aims for commercialization amid a growing market for combination therapies.
Sep 1, 2025
Exploring Drug Patents: Length, Procedure, Obstacles, and Effects in Practice
In the pharmaceutical sector, drug patents are crucial for incentivizing innovation and protecting investments. They typically last 20 years, with potential extensions under the Hatch-Waxman Act. The article discusses the patent process, challenges like generic entry, and the impact of patents on drug pricing and accessibility, highlighting examples like Pfizer's Lipitor® and AbbVie's Humira®.
Sep 1, 2025
The expiration of the Semaglutide patent is set to create significant opportunities for businesses in China.
Semaglutide, known as Ozempic and Wegovy, is set to face increased competition in China as its patent expires in March 2026. Chinese pharmaceutical companies are preparing to launch generic versions, with 16 firms currently developing alternatives. This shift is expected to enhance access to GLP-1 therapies for diabetes and obesity, driving competition and lowering prices in the market.
Aug 31, 2025
Research indicates that fat injections may significantly reduce the risk of early death in heart patients by over 50%.
Recent studies from Harvard University and Novo Nordisk reveal that weight loss injections Mounjaro (tirzepatide) and Wegovy (semaglutide) significantly reduce the risk of early death and hospital admissions in heart failure patients. Mounjaro users had a 58% lower risk, while Wegovy users saw a 42% reduction. These findings highlight potential cardiovascular benefits beyond weight loss.
Aug 31, 2025
Bangladesh faces the possibility of losing its TRIPS waiver as 1000 drug registrations remain pending.
In Bangladesh, 69% of health expenditure is out-of-pocket, with over 1,000 applications for generic and biosimilar drugs pending for nearly two and a half years. Industry leaders warn that the upcoming LDC graduation in November 2026 will end the pharmaceutical patent waiver under TRIPS, potentially raising drug prices significantly, including insulin. The DGDA has yet to decide on these critical applications.
Aug 31, 2025
Bikaner hospital halts antibiotic distribution following illness in children - Drugs Control Media Services
Bikaner's district hospital has suspended the supply of an antibiotic after six children experienced worsening conditions post-administration of intravenous injections. The hospital has sent a sample of the drug for testing to investigate the cause of the adverse reactions.
Aug 31, 2025
Future Directions for the Pharmaceutical Sector - New Era
Bangladesh's upcoming graduation from LDC status in November 2026 poses significant challenges for its pharmaceutical industry, which currently meets 98% of local demand. The end of the TRIPS waiver will restrict local production of patented drugs, raising prices and limiting access. Experts urge immediate action to enhance R&D, strengthen the API sector, and foster innovation to ensure a smooth transition.
Aug 31, 2025
AstraZeneca's Baxdrostat: A Significant Advancement in Managing Hypertension and Opening New Avenues for...
AstraZeneca's baxdrostat has achieved significant Phase III success, showing a 15.7 mmHg reduction in systolic blood pressure for hard-to-control hypertension. This first-in-class aldosterone synthase inhibitor is projected to exceed $5 billion in annual sales by 2030, addressing a critical market need. AstraZeneca plans regulatory filings by late 2025, with approvals expected in 2026, enhancing its Cardiovascular, Renal, and Metabolism portfolio.
Aug 31, 2025
A study reveals that Novo Nordisk's Wegovy reduces heart risk by 57% compared to Lilly's weight-loss medication.
Novo Nordisk's Wegovy, containing semaglutide, demonstrated a 57% reduction in the risk of heart attack, stroke, or death compared to Eli Lilly's tirzepatide-based Zepbound and Mounjaro in overweight and obese patients with cardiovascular disease. The findings, presented at the European Society of Cardiology meeting, highlight Wegovy's potential heart-protective benefits amid increasing competition in the weight-loss market.
